Jonathan LaCombe

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Megan Stringer, Irushi Abeysekera, Jared Thomas et al. · Physiology & Behavior · 2017 · 59 citations · Full text

Life Sciences, Genetics, Neuroscience +8

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice

Charles R. Goodlett, Megan Stringer, Jonathan LaCombe et al. · Scientific Reports · 2020 · 44 citations · Full text

Life Sciences, Genetics, Pharmacology +14

Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome

Jared Thomas, Jonathan LaCombe, Rachel Long et al. · Bone · 2020 · 30 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models

Jamal Raza, Jonathan LaCombe, Roshni Patel et al. · PLoS ONE · 2022 · 22 citations · Full text

Medicine, Genetics, Pharmacology +15

Down syndrome mouse models have an abnormal enteric nervous system

Ellen Merrick Schill, Christina M. Wright, Alisha Jamil et al. · JCI Insight · 2019 · 19 citations · Full text

Life Sciences, Genetics, Pediatrics +17